Podcasts about IDE

This episode covers: • Nano CBD Pain Relief Without Cognitive Side Effects A new nano-micelle formulation of CBD called CBD-IN delivers fast, non-addictive pain relief in mice without memory issues, motor impairment or the usual cannabinoid “fog.” Because it crosses the blood brain barrier and directly targets hyperactive pain circuits, it sidesteps many opioid-type drawbacks. Dave explains why precision-designed cannabinoids could reshape chronic pain treatment and longevity support. Source: https://www.sciencedaily.com/releases/2025/11/251117095652.htm • Moderate Calorie Restriction Slows Biological Aging A long-term trial from the National Institute on Aging found that cutting calories by about 12% over two years slowed the pace of aging — measured by methylation clocks and metabolic markers — in lean and mildly overweight adults alike. Dave breaks down why small, manageable dietary tweaks can deliver big longevity gains, without crash dieting or extreme fasting. Source: https://www.nia.nih.gov/news/cutting-calories-may-slow-pace-aging-healthy-adults • FDA Approves AI-Guided Robotic Surgery Trials for Alzheimer's The U.S. Food and Drug Administration (FDA) has granted IDE approval for the first robotic microsurgical study targeting early stage Alzheimer's disease using AI and deep imaging. The trial uses adaptive robotics to target deep brain lymphatic pathways, potentially clearing amyloid/tau deposits with surgical precision. Dave explains why this signals a new era in neurodegeneration – moving from drug-only to machine-assisted brain repair. Source: https://www.mmimicro.com/ide-approval-for-first-robotic-microsurgery-alzheimers-study/ • Antibiotic Reprograms Gut Bacteria to Produce Anti-Aging Molecules Researchers demonstrated that the veterinary antibiotic cephaloridine can reprogram gut microbes to secrete colanic acid — a molecule linked to better mitochondrial health, reduced gut permeability and improved cholesterol/insulin balance in mice. Dave explores how this could evolve into a pipeline of engineered probiotics that act as internal “longevity factories.” Source: https://newatlas.com/aging/antibiotic-longevity-microbiome/ (link remains unchanged) • Klotho: The Longevity Protein Nears Clinical Reality The longevity protein Klotho, known for clearing toxic by-products, calming inflammation and protecting brain/organ networks, is now advancing toward human trials via injectables, oral formats and gene therapy. Dave explains why Klotho is shaping up as a foundational target for next-gen age-reversal strategies and stacking protocols. Source: https://investingnews.com/longevity-focused-health-fueling-u-s-anti-aging-products-market-projected-to-reach-27-billion-by-2033/ (link remains unchanged) All source links provided for easy reference to the original reporting and research above. This episode is essential listening for fans of biohacking, human performance, functional medicine and longevity who want practical tools from Host ­Dave Asprey and the latest breakthroughs shaping the future of health. Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade gives you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights in health, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence and conscious living. New episodes are released every Tuesday, Thursday, Friday (audio only) and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: nano CBD, CBD-IN, pain relief research, non opioid pain therapies, chronic pain and aging, caloric restriction aging, methylation clocks, metabolic resilience, AI robotics, Alzheimer's microsurgery, neurotech advancement, microbiome engineering, colanic acid, longevity probiotics, mitochondrial support, Klotho protein, anti aging gene therapy, cellular rejuvenation, longevity news, biohacking updates Thank you to our sponsors! LYMA | Go to https://lyma.sjv.io/gOQ545 and use code DAVE10 for 10% off the LYMA Laser. Vibrant Blue Oils | Grab a full-size bottle for over 50% off at https://vibrantblueoils.com/dave. Resources: • Subscribe to my weekly newsletter: https://substack.daveasprey.com/welcome • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps: 0:00 — Intro 0:19 — Story 1: Nano CBD for Pain Relief 1:53 — Story 2: Caloric Restriction and Aging 3:20 — Story 3: AI Robotic Surgery for Alzheimer's 4:50 — Story 4: Microbiome Reprogramming 6:05 — Substack Announcement 7:04 — Story 5: Klotho Longevity Protein 8:39 — Weekly Homework 9:31 — Outro See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Gemini 3.0 just dropped, grabbing the "Best LLM" crown and completing Google's epic AI comeback! We break down the need-to-knows, including:Google's ambitious Antigravity agent-first IDE.Why G3 broke every benchmark except coding.The rise of AI-generated music (1 in 3 streams!).The truth about AI's water usage.The winners and losers after Gemini 3 Day.Plus: A check-in on the AI bubble after Oracle's Open AI deal crash.

You ever see a new AI model drop and be like.... it's so good OMG how do I use it?

Gemini 3 is officially here. ✨ ✨ ✨For about 8 months, Gemini 2.5 Pro has mostly maintained its standing as the top LLM in the world yet Google just unleashed its successor in Gemini 3.0. So, what's new in Gemini 3? And whether you're a developer or casual user, what does Google's new model unlock? Join us as we chat with Google's Logan Kilpatrick's for all the answers. Gemini 3: What's new and what it unlocks for your business with -- An Everyday AI Chat with Google DeepMind's Logan Kilpatrick and Jordan WilsonNewsletter: Sign up for our free daily newsletterMore on this Episode: Episode PageJoin the discussion: Thoughts on this? Join the convo and connect with other AI leaders on LinkedIn.Upcoming Episodes: Check out the upcoming Everyday AI Livestream lineupWebsite: YourEverydayAI.comEmail The Show: info@youreverydayai.comConnect with Jordan on LinkedInTopics Covered in This Episode:Gemini 3 Release Overview & FeaturesState-of-the-Art AI Benchmarks ExceededGemini 3 in Google Ecosystem ProductsGemini 3 Vibe Coding Capabilities DemoNon-Developer Use Cases for Gemini 3Multimodal Understanding and VisualizationsAgentic AI Tools: Gemini Agent & Anti GravityBusiness Growth with Gemini 3 AI IntegrationTimestamps:00:00 Gemini 3: State-of-the-Art AI05:59 "Gemini 3: Build Ambitiously"08:16 "AI Studio: Bringing Ideas Alive"12:44 Gemini App Agents & Anti-Gravity14:57 "Enhancing AI as a Thought Partner"17:01 AI Studio: Build Apps FasterKeywords:Gemini 3, Gemini 3 Pro, Google AI, AI Studio, Vibe Coding, multimodal model, agentic coding, tool calling, anti gravity, generative interfaces, Gemini app, APIs, AI capabilities, interactive experience, visual dashboard, bespoke visualization, state-of-the-art model, developer platform, agentic developer tools, benchmark results, code editor, IDE integration, product experiences, infrastructure teams, triage inbox, personal assistant, proactive agents, 2.5 Pro, model capability, product feedback, code generation, gallery applets, build mode, ambition in AI, software engineering, feature enhancement, thought partner, AI-powered building, on demand experience, interactive visualizations, coding advancements, user engagement, real-time rollout.Send Everyday AI and Jordan a text message. (We can't reply back unless you leave contact info) Head to AI.studio/build to create your first app.  Head to AI.studio/build to create your first app. 

Topics covered in this episode: Possibility of a new website for Django aiosqlitepool deptry browsr Extras Joke Watch on YouTube About the show Sponsored by us! Support our work through: Our courses at Talk Python Training The Complete pytest Course Patreon Supporters Connect with the hosts Michael: @mkennedy@fosstodon.org / @mkennedy.codes (bsky) Brian: @brianokken@fosstodon.org / @brianokken.bsky.social Show: @pythonbytes@fosstodon.org / @pythonbytes.fm (bsky) Join us on YouTube at pythonbytes.fm/live to be part of the audience. Usually Monday at 10am PT. Older video versions available there too. Finally, if you want an artisanal, hand-crafted digest of every week of the show notes in email form? Add your name and email to our friends of the show list, we'll never share it. Brian #1: Possibility of a new website for Django Current Django site: djangoproject.com Adam Hill's in progress redesign idea: django-homepage.adamghill.com Commentary in the Want to work on a homepage site redesign? discussion Michael #2: aiosqlitepool

Niekedy nás zdravie zastaví preto, aby sme našli novú cestu životom. ( INFO: Podujatia ❤ - https://www.40plus.sk/podujatia-odznova/ ❤Info o overených vychytávkach z podcastu LINK: https://www.40plus.sk/vychytavky/ )Liečba červeným svetlom, vodíkom, hydroterapia. Lekári nemohli uveriť, pomohol si sám. Miro Tančin. Odmietame spomaliť. Aj tak by sa dal opísať príbeh pána Tančina. Jedného dňa zistil, že ho zdravie začína blokovať. Presnejšie išlo o chrbticu. Informácie od lekárov zneli jednoznačne: Operácia a už sa len "šetriť“...On sa však rozhodol vyzdravieť. Ako sa mu to podarilo a čo sa potom v jeho živote zmenilo? Aj o tom bol náš dnešný rozhovor. V rozhovore prezradil, čo všetko skúšal a ako ho táto skúsenosť naviedla aj k jeho novému poslaniu.Miroslava nájdete tu: https://www.tanvea.com/kontakt/ alebo mail a tel.: tancin@tanvea.com+421 908 722 270 - píšte heslo VYHODNE a keď, tak dostanete lepšiu cenu, ako je obvyklé. *********************************************************Ďakujem, že ma podporujete na herohero alebo tu na YouTube. Aj vďaka vám vzniká tento obsah. Chcete ma začať podporovať? Info tu: https://herohero.co/odznova Podpora je možná aj tu na YouTube.. zmysel to pre má od 5,99€ (50% z vášho predplatného mi zoberie YouTube ako províziu. Tak si to viete spočítať...Hero berie len 12,5%) Predplatné 2,99 na YT je bez nároku na obsah vopred. Ide len o sympatizovanie, za čo ďakujem... Ak nechcete platiť kartou, možné je podporovať aj cez číslo účtu o.z. : SK45 8330 0000 0022 0165 1060 - do poznámky uveďte, že ide o DAR ĎAKUJEM a nezabudnite pozrieť info a linky o podujatiach a vychytávkach... ( INFO: Podujatia ❤ - https://www.40plus.sk/podujatia-odznova/ ❤Info o overených vychytávkach z podcastu LINK: https://www.40plus.sk/vychytavky/ ) Buďte zdraví Martina Valachová

Do dôchodku vstupuje s dlhom 30 % Američanov a približne pätina Európanov. Ako je to na Slovensku? Aké sú možnosti, ale najmä riziká zadlžovania starších ľudí? V podcaste sa dozviete: Prečo sa v súčasnosti zadlžujú aj ľudia nad 50 rokov v súčasnosti?  Aké sú možnosti a pravidlá natiahnuť si úver až do dôchodkového veku a na druhej strane dostať úver ako dôchodca? Ktoré typy úverov (hypotéky, spotrebné úvery, kreditné karty) predstavujú najväčšie riziko pre finančnú stabilitu tejto vekovej skupiny a prečo? Sú starší ľudia finančne disciplinovanejší?  V akej miere môže klient 10 rokov pred odchodom do dôchodku realisticky odhadnúť svoju budúcu finančnú situáciu a schopnosť splácať? Čelí táto veková skupina reálne hrozbe tzv. "dvojitého šoku" – teda výrazného poklesu životnej úrovne pri prechode na dôchodok, ku ktorému sa pridáva nevyhnutnosť splácať záväzky? Ako sa na úvery v dôchodkovom veku pozerať z pohľadu zhoršovania zdravotného stavu a vyššej potreby peňazí na jeho riešenie? V relácii Ide o peniaze odpovedá Pavel Škriniar z katedry ekonómie Národohospodárskej fakulty Ekonomickej univerzite v Bratislave.

Herečka Natália Germáni patrí k najobsadzovanejším slovenským herečkám svojej generácie, jej život sa však už niekoľko rokov odohráva na dvoch kontinentoch. Medzi Slovenskom a Amerikou pendluje nielen kvôli rodine, ale aj novým pracovným výzvam, ktoré ju formujú ako umelkyňu aj ako človeka.  Do nášho štúdia priletela priamo z New Yorku, aby predstavila svoj nový film Neporaziteľní a otvorene prehovorila nielen o profesionálnom, ale aj súkromnom živote a jeho smerovaní. Práve rola v novej českej dráme Neporaziteľní ju zasiahla hlbšie, ako čakala. „Po natáčaní som si veľa naplakala,“ priznáva herečka.  Tento rok - krátko pred nástupom Donalda Trumpa do úradu - získala v USA pracovné víza. Podarilo sa jej hrať v predstavení na Broadway a natočiť jeden film. Život v Amerike však nie je len o úspechu. Je to aj o neustálom boji o rolu a každodennom dokazovaní svojich kvalít na jednom z najdrsnejších trhov sveta. „Amerika ma naučila povedať si o svoju cenu a nehanbiť sa pochváliť,“ vysvetľuje. Za rozhodnutím skúsiť šťastie za oceánom stál predovšetkým jej manžel. Natália s úsmevom priznáva, že bez jeho impulzu by pravdepodobne nikdy neopustila svoju komfortnú zónu. V rozhovore sme však otvorili aj ďalšie témy. Ako zvláda výchovu dvoch dcér na dvoch kontinentoch? Aké je to natáčať film v ôsmom mesiaci tehotenstva? Ako vníma politickú situáciu v Amerike a či sa jej dotýka ako umelkyne? A prečo by svoje dcéry bez váhania podporila v umeleckej kariére, aj keby mali byť manikérky? Dozviete sa ešte omnoho viac v novej epizóde Ide o nás - Rozhovory so Zdenom Gáfrikom.

Santo Espírito (parte 12) - Gabriel Manzoni by IDE

Kaya and Faisal break down the rise of a Muslim founder whose AI company is now valued at $3B—from coding in a Jordanian internet café and getting rejected by YC four times… to building a browser-based IDE in 2016, then pivoting into agentic AI that codes, debugs, and deploys while you sleep. We pull out the real lessons: grit over hype, "die on the path," and why building within halal limits brings barakah (with cautionary stories about riba). We also spotlight MENSPIRE, a global barbershop chain built on Muslim values (no music, no gossip, family-safe) that still scaled—proof you can build infrastructure for the community without compromising. Plus: dopamine from doing (not doom-scrolling), showing up daily, and being agile like water when markets shift.

Guest Dr. Sundar Jagannath and host Dr. Davide Soldato discuss JCO article "Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma," and the efficacy of CAR-T cell therapy in patients with heavily pretreated RRMM (relapsed/refractory multiple myeloma). TRANSCRIPT Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO author, Professor Sundar Jagannath, Professor of Medicine at the Icahn School of Medicine at Mount Sinai and the Tisch Cancer Institute. He also serves as Network Director for the Center of Excellence for Multiple Myeloma, and he is an internationally recognized expert in the field of multiple myeloma. Today, we will be discussing the article titled, "Long-Term Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma." Thank you for speaking with us, Professor Jagannath. Dr. Sundar Jagannath: Thank you for having me, Dr. Davide Soldato. It is a pleasure to be here. JCO is a highly recognized journal among the oncologists, so I am very happy and privileged to be here today. Dr. Davide Soldato: Thank you so much for being with us. So, I wanted to start a little bit with the rationale of the study and the population that was included in the study. So, the trial that we are discussing, CARTITUDE-1, was already published before, and we observed very good results with a single infusion of cilta-cel. So we had previously reported a median progression-free survival of 30 months, and median overall survival was not reached. So, I just wanted to ask you if you could guide us a little bit into the population that was included in the study and also explain a little bit to our listeners what is the drug that we are discussing, cilta-cel. Dr. Sundar Jagannath: It is a CAR T-cell. This is a patient's own lymphocytes, which goes through apheresis and is sent to the company, where they modify it and introduce the B cell receptor. In this case, you know, there is a heavy chain gene receptor for the BCMA, and in cilta-cel, there are actually two receptor sites on each molecule, or there are two binding domains on each receptor molecule. So, it is considered to be quite efficacious. As you reported, the earlier results that the patients who participated, 97% of the patient responded. Now, you asked about the patients who participated in the clinical trial. This clinical trial was conducted between July of 2018 and October of 2019. At that time, this was a phase 1b/phase 2 trial, and the whole idea was to take patients who had relapsed all the available treatment regimen so that these patients were considered to have, in the unmet medical need situation. So, what does that entail? That means the patient should have been exposed to a proteasome inhibitor, to an immunomodulatory molecule, and to an anti-CD38 monoclonal antibody and should have received at least three or more prior lines of therapy and should be actually progressing on their last line of therapy. So with that requirement, if you look at it, the median number of prior therapy on the patients who participated was actually six. So patients were heavily pretreated. They had exhausted all available treatment options. So, they can participate in this clinical trial. And if not, there have been real-world evidence, such as LocoMMotion, which had reported what is the outcome for such a patient if they were treated outside of this clinical trial, if they were treated with the then available regimen. Their median progression free survival would have been only 3 months, and most patients would have lost their life within a year. So, this was truly an unmet medical need with patients in a very difficult clinical situation. Let's put it that way. So, those were the patients who participated in this particular trial. Dr. Davide Soldato: Thank you very much. And as we mentioned before, the results that were obtained in this clinical trial were really very interesting. And now, in this issue of the Journal of Clinical Oncology, you are reporting data with a longer follow up. So we are actually at more than 5 years of follow up for the patients included in this trial. So, I just wanted a little bit of insight into why you decided to report these long-term outcomes and what type of information do you think you could provide with this study to the medical community? Dr. Sundar Jagannath: This is very important because this was a clinical trial that was done in patients who were, as I said, in unmet medical need. Most of the patients had prior stem cell transplantation, had gone through a proteasome inhibitor. Many of them have had both Velcade and carfilzomib treatment. Most of them had been exposed to lenalidomide and pomalidomide. And as required, all of the patients had to have had prior exposure to anti-CD38 monoclonal antibody or daratumumab. So, the patients were heavily pretreated. Typically, TIL CAR T-cells came into the field at this particular moment, until then, we were developing small molecules, and they usually would have a PFS of 3 months and median life expectancy of a year, the overall response rate of 30%, and that is how, if you look back, that is how carfilzomib was approved, that is how pomalidomide was approved. So, the drugs which were approved, including daratumumab, you know, the response rate was in the same ballpark. So you would see that most agents, single agents, would have had a response rate in the neighborhood of 30%, the progression-free survival would have been between 3 to 5 months or 6 months at the most, and the life expectancy was short. And here comes a drug, and when I was following the patients at Mount Sinai, I found that there were a subset of patients, they got one-time treatment and they were in complete remission, no trace of cancer with annual evaluation with PET CT and bone marrow evaluation for MRD. So, I said this is remarkable, and this needs to be reported. And I went to the Janssen and company, and they agreed to review the entire experience. This is remarkable that 32 of the 97 patients, or one third of the patients, were alive and progression-free. This is unheard of for any clinical trial until now, that the patient will be progression-free, one third of the patients on a clinical trial will be progression-free, in the late stage of their disease. So that is the most important impact. And that is why this 5-year follow-up results were presented. Dr. Davide Soldato: Thank you very much. That was very clear. And as you said, we are speaking about a population that was heavily pretreated, that had exhausted all type of treatment options outside of a clinical trial. And as you said, one third of the patients was alive and progression-free after 5 years from being included and infused inside of the study. So, considering this population that, as we said, had received all treatment options, I was wondering if you observed any kind of differences in terms of disease characteristics when looking at these patients that had exceptional response, so, alive and progression-free at 5 years, and the patients that sadly had developed a progression after the infusion in the study. Dr. Sundar Jagannath: This is very important because we wanted to see who are the patients who are having this exceptional outcome. And we looked at all the 97 patients. If we look at all the patients, we saw that there were initially, out of the 97, 17 patients died earlier in the disease course due to treatment related complications, etc. But there were about 46 patients who had progression of disease and 32 patients, or one third, were alive without progression of disease. Then we looked at the 46 patients who had progression of disease. Of them, we found that 30 had disease progression and its complication, and there were actually 13 patients who were still alive even after progression of disease. So we decided to compare these 46 patients who had progression of disease versus 32 patients who had no progression of disease to see what is the difference. To our surprise, the age was similar, male, female distribution was similar. High-risk cytogenetics, which we would have thought, you know, that is why we say high-risk disease, the term, high-risk cytogenetics was equally distributed. That was really a surprise. Number of lines of prior therapy, number of exposure to drugs, all of that was the same. So that was also interesting. But a theme did emerge. Patients, in general, tend to have lower burden of disease who had the exceptional outcome. But there is one which we considered as bad, the extramedullary disease. Multiple myeloma being a blood cancer, it is usually in the bone marrow. When it starts growing outside of the bone marrow, the extramedullary disease, usually it portends poor prognosis. But we were surprised that actually there were an equal number of extramedullary disease patients even in the long-term survivor as those who had progressed of disease. So the most important takeaway was patients who had lower burden of disease, they had less number of myeloma cells in their bone marrow, percentage wise, and the soluble BCMA level was lower. Soluble BCMA is an indirect measure of the amount of plasma cells in the patient's body. It is like a tumor burden. So they were low. So, this was an important finding because it has future ramification, as you can understand. If this treatment is made available earlier in the disease course of the patients, where we are able to control the disease better, then more patients are likely to have such wonderful outcomes as one third of the patient experience in the late stage of the disease. Dr. Davide Soldato: So, you already mentioned soluble BCMA as a marker of potentially better prognosis as being correlated to a lower volume of disease. I was wondering if you could give us some more information about the biomarkers that you evaluated in the study. For example, you evaluated a little bit the CAR T expansion kinetics and also some others that I think could be interesting and could point to some population that experienced such important benefit. Dr. Sundar Jagannath: That is a very important point because CAR T-cell, it is a live cell and its efficacy depends upon how well the CAR T-cell is going to function. And then, you know, the patient undergoes apheresis. This is a patient's own lymphocyte. So first and foremost is who would generate good CAR T-cell. Those who have plenty of lymphocytes at the time they are coming for apheresis. This is likely to happen earlier in the course of the disease than in patients who have gone through numerous lines of therapy and exhausted. So, in this particular trial, of course this was in late stage of the disease, and so we were able to show patients who had lower number of T cell in circulation, and the way to measure is if they had more neutrophils and less lymphocytes. So that is what is called as a higher T cell over neutrophil, they did better. If they have more neutrophil than T cells, then they did not do well. So, procurement. The second one is also whether the T cells are more naive, you know, not exhausted T cells. So more naive T cells, if you are able to procure from the patient, they did very well. Now, after the CAR T-cell manufacture, then the expansion, when you put it back into the patient, if the T cells expand very well, so that the effector, that is the CAR T-cells to the tumor ratio is good, so there are more effector cells, the CAR T was able to expand and the amount of tumor was less, then the efficacy was very, very good. As I said, the patients in this group, those who had a lower burden of disease, they did better, and that is because of the CAR T-cell expansion, so the effector to the target ratio was favorable. So that is another important. And then there are also the type of CAR T-cells, having CD4 T cells with central memory phenotype at the peak expansion also makes a difference. So all of that matters. But this is important because the efficacy of the CAR T-cell, it is persistent, long persistent and keeping the cancer down. Its ability to get rid of the cancer completely at the first go around because usually we are not able to detect the CAR T-cells beyond 6 months in the majority of patients and very rarely after a year or two. So it is very uncommon to find the CAR T-cells in circulation or even in the regular bone marrow evaluation. So, efficacy, the expansion, having naive T cells, having good effector to target ratio and more central memory kind of T cell, because if it is all effector T cell, they will get quickly utilized and get exhausted, whereas the central memory cells can expand more and give more effective CAR T-cells. Dr. Davide Soldato: Thank you very much. I was wondering if you could guide us a little bit into what is your opinion regarding the positioning of CAR T-cells given all of these logistics that is necessary compared, for example, with bispecific antibodies against BCMA, which have the same target, but they do not have all of these logistics before being administered to the patient. Dr. Sundar Jagannath: That is a very important question, how to sequence these treatments now that we have two BCMA-directed CAR T-cells available. We have three BCMA-directed bispecific and one GPRC5D-directed bispecific antibodies are available. And so the question comes in for at least the currently approved CAR T-cell therapy, there is an obligatory time. You have to go through apheresis and you have to ship to the company, and there is a manufacturing time, roughly about 2 months before they can receive it. During that time, you want to make sure the patient's disease is under control. So that is a given. There are several ways to look at it when we evaluate the patient and talk to the patient. One good thing is now the two CAR T-cells which are approved, one is cilta-cel we talked about, and the other one is ide-cel. Ide-cel is approved in earlier line of therapy, two or more prior lines of therapy, and cilta-cel is approved in patients who have failed one line of therapy and who are lenalidomide refractory. So, the treatment of CAR T-cell is available earlier. And as I said, when you administer CAR T-cell earlier, you are able to keep the disease burden down, and it is a one and done deal. There is a better quality of life for the patient, and you are able to produce long, durable remission and potentially a cure. Now coming to the bispecific, they are currently available in later lines of therapy. So if you look at it from a patient's perspective, you can use the CAR T-cell earlier and then go through the bispecific therapy. But if the patient comes with relapsed refractory myeloma and has not used the CAR T-cell therapy and has not used the bispecific therapy, then the physicians have to decide which one they want to use. If somebody's disease is rapidly progressing and they need immediate tumor reduction and they have already exhausted all available therapy, then going through BCMA bispecific therapy is quite appropriate. And secondly, CAR T-cell therapy is generally given to somewhat physically more fit patients, whereas bispecific therapy, because you are giving antibody at step-wise dosing in this patient, and you have the ability to stop at any particular dose and then come back and redose, whereas CAR T is, you just give it to them one time, you have a lot more control. So intermediate frail or even frail patients can go through bispecific therapy, whereas it would not be in the best interest of the patient to go through a CAR T-cell therapy when they are frail. So that is another important point. But from the information available, when the patient goes on a BCMA bispecific therapy and they start progressing on treatment, usually it is their T cells are exhausted or the BCMA is no longer expressed on the tumor cells. So coming with CAR T-cell later on is usually not effective, whereas giving CAR T-cell earlier, if the patient relapses later, they have good T-cell function and most of the time the BCMA is still expressed. So you are able to give the BCMA to the maximum benefit by using the CAR T first and BCMA later. So if somebody asked me how to sequence this, just off the bat, you will say CAR T first, BCMA bispecific second. But as I said, there are unique situations. Then there is another potential that is happening. You can change the target. You can use a BCMA against GPRC5D to reduce the tumor, and then go ahead and consolidate it with a CAR T-cell therapy. That is also possible. You are changing the target from GPRC5D to BCMA, the tumor is already down, so the patient is likely to benefit. So these are all newer treatment options which have become available to the physician. So they will have to look at individual patients and decide what is the best course of action for that patient. Dr. Davide Soldato: So, I just wanted to close a little bit with your opinion about how these results translate into clinical practice. So considering this outstanding 5-year data that we have seen, one third of the patients who are alive and progression-free after a single infusion of cilta-cel, do you think that we could start to think about functional cure even in patients who have a diagnosis of relapsed refractory multiple myeloma? Dr. Sundar Jagannath: My feeling is this is important because in this particular study which is published, 12 patients who were followed at Mount Sinai out of the 32 patients who are alive and progression-free, 12 were followed at Mount Sinai. And they were evaluated every year with bone marrow MRD testing by clonoSEQ in 11 of the 12 patients, and one was by multiparametric flow cytometry. So most of them were 10 to the minus 6, not even one in a million cancer cells, and all of them had functional imaging, which is called PET CT every year. So these were patients who had no evidence of disease that we could detect with the technology available today, serologically, in the bone marrow, or anywhere else in the body with a PET CT. They were found to be disease free after a single infusion of cilta-cel. So, that would be almost to the definition of a cure because if you look at cure as a definition for any cancer, cure is defined as a state of complete remission with no trace of cancer that persists over a period of 5 years or longer without maintenance. And that will be applicable for breast cancer, lymphoma, leukemia. So it is a general statement. And if we use that in myeloma too, then I could say that these 12 patients from my center, we proved that they are cured of their myeloma. They are not functionally cured. You've got to remember, there is only cure. That was the definition across all diseases. So there is nothing like a functional cure. They are cured of myeloma. So is myeloma curable? This is the first time we are looking at that. We do know, every physician treating myeloma that there are patients out there, 10 year and beyond, without evidence of disease. This has been published by University of Arkansas, Bart Barlogie's group, who has been saying that myeloma is a curable disease for a long time. And many others have shown long-term follow up. But this one in a late stage disease, we were able to show that they were one treatment with no maintenance. All other studies have been in newly diagnosed myeloma patients. Nobody has shown in late relapse patients on a clinical trial a third of the patient will be progression-free. And 12 of them who were studied were actually disease free. So they were cured of the disease. So if we accept that, then the next question is, first step towards cure is achieving complete remission. They should have no monoclonal protein by any technology you want to use, no measurable residual disease using next gen sequencing or clonoSEQ, and functional imaging whole body PET CT or whole body MRI. So that is important, definition of the complete remission. And then it has to be sustained. That is something the IMWG and IMS, International Myeloma Society, they will have to come together for a consensus. How many years should they be followed and should be in this kind of status with no trace of cancer? Is it, 3 years are enough? 4 years enough? 5 years is enough? For me, I said in this paper, 5 years is a good definition for achieving a potential cure. Then you use the term 'functionally cured'. I have a problem with functionally cured and operationally cured or whatever. Functionally cured was originally put out by Paiva from Spain. There were 8% of newly diagnosed myeloma patients who have, after they go get treated, they will have an MGUS like phenomenon, a small amount of paraprotein detectable, and they are only 8%. And he said that these patients could be off treatment and the disease does not progress. But the problem is when you are giving treatment like maintenance therapy continuously until progression, you do not know exactly who is in the MGUS situation. So you have to have done sophisticated flow cytometry like Paiva did, and it is not quite clinically applicable. So functionally cured applies only for 8% of the people, so it should go out of the vocabulary. Then you can say 'operationally cured'. These are the patients traditionally Bart Barlogie and others showed that they have a large number of patients who have been followed for 10 years with no recurrence of disease, not on treatment. But in those days, they did not have MRD PET CT and all of them done systematically. So that is why they had to come up with a situation where they said they were operationally cured. So yes, myeloma patients have been cured since auto transplant was introduced. I completely agree. It is not new to the CAR T-cell therapy. But the beauty of the CAR T-cell therapy was it was in relapsed refractory myeloma, unmet medical need, number one. Number two, they were studied systematically. It was a clinical trial adjudicated by FDA and EMA for drug approval, cilta-cel was approved. So these patients were carefully followed, and it was a multi-center study. And in that group of patients, we were able to show patients- So, I think this would indicate cure is a reality in myeloma, and as these kind of treatments, immunologic treatment, either it is a CAR T-cell therapy or BCMA bispecific or whatever, there is a chance more patients are likely to be cured, and these treatments have to move forward and so that we are looking towards a cure. That is the beauty of it, and I just thank you for asking and also throwing in this so-called functionally cured, which people like to use casually, and I say it is time to talk more cure and not stuck with functionally cured because that does not allow the field to progress. Dr. Davide Soldato: Thank you very much. That was very interesting. Dr. Sundar Jagannath: And provocative. Dr. Davide Soldato: A little bit, but I think that we needed to close the podcast with this kind of reflection coming from someone who is an expert in the field, as you are. So, I really wanted to thank you for joining us today and for sharing more on your article, which is titled, "Long-Term Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma." If you enjoy our show, please leave us a rating and a review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. Dr. Sundar Jagannath: Thank you. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

Cumprir o IDE é viver a verdadeira liberdade em Jesus.

Niekto zeleninu a ovocie z obchodu nechce ani vidieť! Je to mŕtva hmota?! Takáto je krutá realita! Zmeň to jednoducho. ( INFO: Podujatia ❤ - https://www.40plus.sk/podujatia-odznova/ ❤Info o overených vychytávkach z podcastu LINK: https://www.40plus.sk/vychytavky/ )Rozhovor o tom, ako si zabezpečiť potraviny pre svoju rodinu. Čo obsahuje ovocie a zelenina z obchodu? V podstate nič. Čo zelenina a ovocie, ak sa pestujú regeneratívne? Je to na úrovni liečivej zeleniny a ovocia... tak vyšli testy, ktoré sa robili... Rozhovor nielen pre tých, ktorí majú záhradu...Želám príjemné sledovanie...Bohuša nájdete na https://bohus.buday.sk/ na knihu a online kurzy dal Bohuš aj zľavu... kupón ROZUM*******************************************************Ďakujem, že ma podporujete na herohero alebo tu na YouTube. Aj vďaka vám vzniká tento obsah. Chcete ma začať podporovať? Info tu: https://herohero.co/odznova Podpora je možná aj tu na YouTube.. zmysel to pre má od 5,99€ (50% z vášho predplatného mi zoberie YouTube ako províziu. Tak si to viete spočítať...Hero berie len 12,5%) Predplatné 2,99 na YT je bez nároku na obsah vopred. Ide len o sympatizovanie, za čo ďakujem... Ak nechcete platiť kartou, možné je podporovať aj cez číslo účtu o.z. : SK45 8330 0000 0022 0165 1060 - do poznámky uveďte, že ide o DAR ĎAKUJEM a nezabudnite pozrieť info a linky o podujatiach a vychytávkach... ( INFO: Podujatia ❤ - https://www.40plus.sk/podujatia-odznova/ ❤Info o overených vychytávkach z podcastu LINK: https://www.40plus.sk/vychytavky/ ) Buďte zdraví Martina Valachová

11 Aconteceu que, caminhando para Jerusalém, Jesus passava entre a Samaria e a Galileia. 12 Quando estava para entrar num povoado, dez leprosos vieram ao seu encontro. Pararam à distância, 13 e gritaram: "Jesus, Mestre, tem compaixão de nós!" 14 Ao vê-los, Jesus disse: "Ide apresentar-vos aos sacerdotes". Enquanto caminhavam, aconteceu que ficaram curados. 15 Um deles, ao perceber que estava curado, voltou glorificando a Deus em alta voz; 16 atirou-se aos pés de Jesus, com o rosto por terra, e lhe agradeceu. E este era um samaritano. 17 Então Jesus lhe perguntou: "Não foram dez os curados? E os outros nove, onde estão? 18 Não houve quem voltasse para dar glória a Deus, a não ser este estrangeiro?" 19 E disse-lhe: "Levanta-te e vai! Tua fé te salvou".

Topics covered in this episode: httptap 10 Smart Performance Hacks For Faster Python Code FastRTC Explore Python dependencies with pipdeptree and uv pip tree Extras Joke Watch on YouTube About the show Sponsored by us! Support our work through: Our courses at Talk Python Training The Complete pytest Course Patreon Supporters Connect with the hosts Michael: @mkennedy@fosstodon.org / @mkennedy.codes (bsky) Brian: @brianokken@fosstodon.org / @brianokken.bsky.social Show: @pythonbytes@fosstodon.org / @pythonbytes.fm (bsky) Join us on YouTube at pythonbytes.fm/live to be part of the audience. Usually Monday at 10am PT. Older video versions available there too. Finally, if you want an artisanal, hand-crafted digest of every week of the show notes in email form? Add your name and email to our friends of the show list, we'll never share it. Michael #1: httptap Rich-powered CLI that breaks each HTTP request into DNS, connect, TLS, wait, and transfer phases with waterfall timelines, compact summaries, or metrics-only output. Features Phase-by-phase timing – precise measurements built from httpcore trace hooks (with sane fallbacks when metal-level data is unavailable). All HTTP methods – GET, POST, PUT, PATCH, DELETE, HEAD, OPTIONS with request body support. Request body support – send JSON, XML, or any data inline or from file with automatic Content-Type detection. IPv4/IPv6 aware – the resolver and TLS inspector report both the address and its family. TLS insights – certificate CN, expiry countdown, cipher suite, and protocol version are captured automatically. Multiple output modes – rich waterfall view, compact single-line summaries, or -metrics-only for scripting. JSON export – persist full step data (including redirect chains) for later processing. Extensible – clean Protocol interfaces for DNS, TLS, timing, visualization, and export so you can plug in custom behavior. Example: Brian #2: 10 Smart Performance Hacks For Faster Python Code Dido Grigorov A few from the list Use math functions instead of operators Avoid exception handling in hot loops Use itertools for combinatorial operations - huge speedup Use bisect for sorted list operations - huge speedup Michael #3: FastRTC The Real-Time Communication Library for Python: Turn any python function into a real-time audio and video stream over WebRTC or WebSockets. Features

This interview was recorded for the GOTO Book Club.http://gotopia.tech/bookclubRead the full transcription of the interview here:https://gotopia.tech/episodes/393Victor Grazi - Oracle Java Champion & Co-Author of "Real-World Java"Jeanne Boyarsky - Oracle Java Champion, Co-Author of "Real-World Java" & "OCP 21 Java Cert Book"Barry Burd - Professor at Drew University, Owner at Burd Brain Consulting & Author of "Java for Dummies"RESOURCESVictorhttps://x.com/vgrazihttps://www.linkedin.com/in/victorgraziJeannehttps://bsky.app/profile/jeanneboyarsky.bsky.socialhttps://www.linkedin.com/in/jeanne-boyarskyBarryhttps://x.com/allmycodehttps://www.linkedin.com/in/barry-burdLinkshttps://projectlombok.orghttps://www.selikoff.net/2014/12/07/why-i-like-regular-expressions-who-says-they-arent-readableDESCRIPTIONBarry interviews Victor and Jeanne  about their book "Real-World Java: Helping You Navigate the Java Ecosystem".Victor emphasizes that knowing how to use your development tools, particularly IDE refactoring features, is a better indicator of developer experience than algorithm tests.Rather than just teaching "hello world" examples, the authors focus on the essential ecosystem components needed to succeed in enterprise Java environments, making it accessible for anyone who knows the Java language but needs to understand the broader technological landscape they'll encounter in professional development roles. RECOMMENDED BOOKSVictor Grazi & Jeanne Boyarsky • Real-World Java • https://amzn.to/4oCEeBRJeanne Boyarsky &Inspiring Tech Leaders - The Technology PodcastInterviews with Tech Leaders and insights on the latest emerging technology trends.Listen on: Apple Podcasts Spotify Canada NowBold ideas with the people shaping Canada's next chapter.Listen on: Apple Podcasts SpotifyBlueskyTwitterInstagramLinkedInFacebookCHANNEL MEMBERSHIP BONUSJoin this channel to get early access to videos & other perks:https://www.youtube.com/channel/UCs_tLP3AiwYKwdUHpltJPuA/joinLooking for a unique learning experience?Attend the next GOTO conference near you! Get your ticket: gotopia.techSUBSCRIBE TO OUR YOUTUBE CHANNEL - new videos posted daily!

Today we're digging into the Model Context Protocol, or MCP. Think LSP for AI: build a small Python service once and your tools and data show up across editors and agents like VS Code, Claude Code, and more. My guest, Den Delimarsky from Microsoft, helps build this space and will keep us honest about what's solid versus what's just shiny. We'll keep it practical: transports that actually work, guardrails you can trust, and a tiny server you could ship this week. By the end, you'll have a clear mental model and a path to plug Python into the internet of agents. Episode sponsors Sentry AI Monitoring, Code TALKPYTHON NordStellar Talk Python Courses Links from the show Den Delimarsky: den.dev Agentic AI Programming for Python Course: training.talkpython.fm Model Context Protocol: modelcontextprotocol.io Model Context Protocol Specification (2025-03-26): modelcontextprotocol.io MCP Python Package (PyPI): pypi.org Awesome MCP Servers (punkpeye) GitHub Repo: github.com Visual Studio Code Docs: Copilot MCP Servers: code.visualstudio.com GitHub MCP Server (GitHub repo): github.com GitHub Blog: Meet the GitHub MCP Registry: github.blog MultiViewer App: multiviewer.app GitHub Blog: Spec-driven development with AI (open source toolkit): github.blog Model Context Protocol Registry (GitHub): github.com mcp (GitHub organization): github.com Tailscale: tailscale.com Watch this episode on YouTube: youtube.com Episode #527 deep-dive: talkpython.fm/527 Episode transcripts: talkpython.fm Theme Song: Developer Rap

Hosťom podcastu bol realitný expert a CEO spoločnosti Equilibrio Syntra a spoluzakladateľ projektu Môjkaštieľ.sk Richard Gál.V podcaste sa dozviete:• ako sa stať akcionárom historického kaštieľa Dezasse,• čím je výnimočný kaštieľ Dezasse,• prečo bude kaštieľ psychologicko - pobytové zariadenie,• ako sa budú v kaštieli prepájať biznisové komunity,• aký výnos z investovania do kaštieľa Dezasse môžete očakávať,• koľko investorov sa môže zapojiť a aké benefity ich čakajú.Môj kaštieľ je unikátna forma investovania na Slovensku. Ako sa môžem stať investorom? Investorom sa môžeš stať veľmi jednoducho. Ideš na stránku Môjkaštieľ.sk. Tam si vyplníš registračné údaje, môžeš podpísať na diaľku zmluvu, odošleš túto zmluvu, no a potom urobíš investičný vklad. Takže procesne je to veľmi jednoduché. Tá cesta je naozaj veľmi jednoduchá. Až neuveriteľná, že takto jednoducho sa dá prísť ku kaštieľu. Aká je minimálna suma, ktorú musím zainvestovať?Minimálna suma, od ktorej už môžeš rozmýšľať o investícii, je suma 4800 eur. To je 40 akcií, z ktorých každá akcia stojí 120 eur. Takže od tejto sumy už potom v násobku 120 eur môžeš investovať. No a môžeš sa stať spoluvlastníčkou alebo parciálnou vlastníčkou tohto kaštieľa.Čím je výnimočný historický kaštieľ Dezasse?Je to kaštieľ, ktorý bol postavený v 18. storočí. Našťastie nie je národnou kultúrnou pamiatkou. Hovorím to preto, pretože tam nie sú nejaké obštrukcie zo strany Pamiatkového úradu. Tento kaštieľ bol zrekonštruovaný naposledy na prelome okolo roku 2000, kedy tam bola pristavaná aj wellness zóna, a pred štyrmi rokmi takisto prešiel celkovou rekonštrukciou. Úplne sa obnovill interiér a dostal sa tam aj najväčší garden partystan na Slovensku.Tento kaštieľ sa má stať psychologicko - pobytovým zariadením. Prečo ste sa rozhodli ísť týmto smerom?Veríme tomu, že je potrebné, aby sme vytvorili udržateľné projekty. A všimli sme si aj z rozhovorov s viacerými psychológmi, aj takisto je to spoločenský trend, že je tu množstvo ľudí, ktorí potrebujú takúto pomoc, nakoľko možno trpia nejakými ľahkými závislosťami. Sú to napríklad alkoholici alebo sa stávajú závislými od mobilu. A je to už niečo, kde už im nestačí klasická ambulantná liečba, ale je treba, aby títo klienti boli v špeciálnom zariadení. Aby tam boli niekoľko týždňov, dokonca možno niekoľko mesiacov, aby nakoniec po tejto liečebnej kúre sa mohli znova stať plnohodnotnými členmi spoločnosti.Tak preto sme si povedali, že tento kaštieľ vzhľadom aj na jeho lokalitu, aj na to, ako je koncepčne usporiadaný, tak bude ideálnym miestom, aby klienti dostali takúto pomoc. Je tam veľmi pekné prostredie. Kaštieľ nádherne zrekoštruovali a môžu si tam naplno užívať pobyt.Historický kaštieľ Dezasse má slúžiť aj na prepájanie ľudí z biznisu na tzv. networking. Zapojené sú tam aj viaceré komunity, ako napríklad Forbes Grow Club alebo Bez cyklenia. Prečo sa tieto komunity zapojili do tohto projektu?Na pozemku sa nachádza najväčší garden párty stan na Slovensku. My sme tam napríklad mali jeden event, na ktorom bolo 270 investorov. Tento stan má kapacitu až okolo 500 až 600 ľudí. Tak vznikla myšlienka, aby sme priamo v rámci tohto konceptu realizovali dva podnikateľské zámery.A jeden z týchto zámerov by práve bolo vytváranie takýchto networkingových stretnutí, kde by nešlo o prepájanie ľudí v rámci komunity, ale dokonca o prepájanie komunít. Takže preto aj Forbes

V relácii Ide o peniaze sa dozviete: Na úvod anketa s mladými Bratislavčanmi: Ako bývajú a majú na vlastný byt? Môže Generácia Z vstupom na trh ovplyvniť ceny realít či úrokové sadzby hypoték? Ako sa má mladý človek vyrovnať s paradoxom, že kým si šetrí na vlastné zdroje, cena nehnuteľnosti v tom istom čase rastie?  Aký príjem v čistom potrebuje mladý človek, aby vôbec dostal priemernú hypotéku vo výške 120-tisíc? Aké sú najefektívnejšie možnosti získať chýbajúcich 10 – 20 % vlastných zdrojov? Aké sú najčastejšie chyby, ktorých sa dopúšťajú rodičia pri ručení pre svoje deti a aké to má riziká? Banky ponúkajú aj 90 % hypotéky. Aká je šanca, že ju mladý klient dostane a aké sú parametre takejto hypotéky? Aký je reálny rozdiel v maximálnej výške hypotéky, ktorú si dokáže zobrať jeden človek a pár s dvoma príjmami?  Aké sú špeciálne rady pre „singles“, ktorí chcú bývať vo väčších mestách? Kúpa vlastnej nehnuteľnosti a možnosť dostať hypotéku: nielen Generácii Z poradí Michal Ďuriš, partner spoločnosti Umbrella Group.

Poslanec hnutia Slovensko Marek Krajčí v relácii Ide o pravdu obhajoval svoje sporné hlasovanie za novelu Ústavy, ktorú podporil spolu s koalíciou. Tvrdí, že rozhodnutie nebolo o spolupráci s premiérom, ale o hodnotách, ktorým dlhodobo verí.

Hypotéza 38: Ako Božia milosť často učí tých, ktorí sa o seba starajú a zverujú sa do jeho prozreteľnosti, ktorá ich vedie prostredníctvom jednoduchých ľudí a cudzincov; pokorní sa neodmietajú učiť od každého, koho môžu stretnúť.   Filokalia Live - pravidelné online formačné stretnutia. Zámerom je spoznávanie a osvojovanie umenia duchovného života štúdiom učenia svätých otcov. Štvrtkové stretnutia sú venované uvažovaniu nad dielom Evergetinos. Ide o rozsiahlu zbierku výrokov a krátkych príbehov zo života púštnych otcov, ktorá bola zostavená mníchom Pavlom v 11. storočí. Každá kapitola dáva dôkladné vysvetlenie predstavenej témy a postupne čitateľa sprevádza od položenia základných kameňov duchovného život až po jeho výšiny. Stretnutia sa konajú každý pondelok a štvrtok o 20.00 hod. V prípade záujmu sa môžete zaregistrovať a e-mailom Vám bude zaslaný link pre vstup na stretnutie.  

Santo Espírito (parte 11) - Gabriel Manzoni by IDE

In this episode of Let's Combinate: Drugs + Devices, host Subhi Saadeh speaks with Leonel Venegas, a seasoned quality and regulatory professional who has worked with global leaders including Alexion, Merck, Johnson & Johnson (Ethicon & Cordis), Amgen, and Medtronic.Leonel shares how integrating Good Laboratory Practices (GLP), Good Clinical Practices (GCP), and Good Pharmacovigilance Practices (GVP) is essential to successful combination-product development. He discusses his journey from chemist to regulatory-affairs expert, uncovering common disconnects between pharma and device cultures, and the critical role of design controls, risk management, and timelines.The conversation also explores GMP and process validation, IDE vs. IND pathways, the challenges of rare-disease programs, and how understanding the cost of quality can reshape testing strategies. Leonel closes by reflecting on becoming a Lean Six Sigma Black Belt and what continuous improvement really looks like in combination-product development.⏱ Timestamps00:00 – Welcome & Introduction00:52 – Integrating GLP, GCP & GMP02:22 – Challenges in Developing Combination Products04:02 – Device-Led Combination Products07:35 – Working with Rare Diseases09:58 – GMP & Process Validation15:08 – Clinical Trials: Drug vs Device19:22 – Cost of Quality & Six Sigma25:12 – Conclusion & Contact InformationLeonel Venegas is the Founder of Precision Regulatory Consulting LLC and an expert in quality and regulatory affairs with over two decades of experience across six global pharma and medtech leaders, including Alexion, Merck, Johnson & Johnson (Ethicon & Cordis), Amgen, and Medtronic.He is certified by ASQ as a CMQ/OE, CQE, CBA, and CSSBB, and holds an M.S. in Regulatory Affairs. Leonel specializes in combination products, medical devices, and IVDs, integrating GLP, GCP, GMP, and GVP principles into complex global development programs.

Snaha ministra Huliaka vyliečiť chorľavý štátny rozpočet príjmami zo štátneho hazardu sa stretol s veľkou kritikou samospráv i odborníkov. Slovensko totiž už dnes zápasí s epidémiou závislostí, medzi ktoré nepochybne patrí aj gambling. Je teda naozaj dobrý nápad vyrábať z Detvy akési slovenské Las Vegas a ako na tom vlastne Slovensko je v oblasti závislostí?Riziká hazardu, teda patologickej závislosti na hraní, sú obrovské a dnes už aj veľmi dobre známe. Ide o chorobnú závislosť, ktorá patrí medzi duševné poruchy, svoje obete dokáže finančne úplne zruinovať, dohnať ich k nesplatiteľným dlhom, kriminálnej činnosti, ťažkým psychickým problémom, ako i rozvratu ich sociálnych väzieb. Okrem gamblerov tak môžu trpieť aj ich rodiny či dokonca i vlastné deti.Stoja teda potenciálne zisky zo štátneho hazardu za všetky tieto ľudské obete i nemalé ekonomické straty? Ako na tom vlastne táto spoločnosť je v oblasti závislostí - od tabaku, cez alkohol, gambling až po nelátkové závislosti ako sú internet, sociálne siete či dokonca porno? Je poctivé na jednej strane horovať za tradičné kresťanské hodnoty a na strane druhej bohatnúť na hazarde a utrpení rodín patologických gamblerov? Čomu aktuálne v tejto oblasti čelia deti a majú to dnes ťažšie, než sme to mali my - ich rodičia? No a napokon, nakoľko sme v tomto - ako spoločnosť - sami voči sebe úprimní a poctiví a naozaj chceme tieto problémy riešiť a nie pred nimi utekať alebo ich dokonca spoločensky normalizovať?To sú témy dnešného podcastu s adiktológom - teda odborníkom na závislosti - Rastislavom Žemličkom. Počúvate Aktuality Nahlas, pekný deň a pokoj v duši praje Braňo Dobšinský.

Send us a textIn this episode of Embedded Insiders, the VP of Sales and Business Development at Gateworks Corporation, Kelly Peralta, joins me to discuss the trends, challenges, and innovations surrounding Wi-Fi HaLow for industrial and IoT applications.The next segment is sponsored by Analog Devices, and Contributing Editor, Rich Nass, and Analog Devices' Senior Vice President of Software and Digital Platforms, Rob Oshan, discuss the complexity of designing AI systems and how Analog Devices' CodeFusion Studio, which includes an IDE, a software development kit, and coding tools, is designed to accelerate the process. Check out the embedded world North America 2025 Best-in-Show winners. For more information, visit embeddedcomputing.com

Snaha ministra Huliaka vyliečiť chorľavý štátny rozpočet príjmami zo štátneho hazardu sa stretol s veľkou kritikou samospráv i odborníkov. Slovensko totiž už dnes zápasí s epidémiou závislostí, medzi ktoré nepochybne patrí aj gambling. Je teda naozaj dobrý nápad vyrábať z Detvy akési slovenské Las Vegas a ako na tom vlastne Slovensko je v oblasti závislostí?Riziká hazardu, teda patologickej závislosti na hraní, sú obrovské a dnes už aj veľmi dobre známe. Ide o chorobnú závislosť, ktorá patrí medzi duševné poruchy, svoje obete dokáže finančne úplne zruinovať, dohnať ich k nesplatiteľným dlhom, kriminálnej činnosti, ťažkým psychickým problémom, ako i rozvratu ich sociálnych väzieb. Okrem gamblerov tak môžu trpieť aj ich rodiny či dokonca i vlastné deti.Stoja teda potenciálne zisky zo štátneho hazardu za všetky tieto ľudské obete i nemalé ekonomické straty? Ako na tom vlastne táto spoločnosť je v oblasti závislostí - od tabaku, cez alkohol, gambling až po nelátkové závislosti ako sú internet, sociálne siete či dokonca porno? Je poctivé na jednej strane horovať za tradičné kresťanské hodnoty a na strane druhej bohatnúť na hazarde a utrpení rodín patologických gamblerov? Čomu aktuálne v tejto oblasti čelia deti a majú to dnes ťažšie, než sme to mali my - ich rodičia? No a napokon, nakoľko sme v tomto - ako spoločnosť - sami voči sebe úprimní a poctiví a naozaj chceme tieto problémy riešiť a nie pred nimi utekať alebo ich dokonca spoločensky normalizovať?To sú témy dnešného podcastu s adiktológom - teda odborníkom na závislosti - Rastislavom Žemličkom. Počúvate Aktuality Nahlas, pekný deň a pokoj v duši praje Braňo Dobšinský.

There are lots of semiconductor vendors that do a great job of providing AI hardware. But unfortunately, for many of them, their offerings end there, requiring developers to source software and tools from multiple sources. It's no secret that designing a system with AI is complex enough. Having to go to different vendors for different pieces just adds multiple layers of complexity. Analog Devices is taking a different tack, where they are providing just about everything the developer needs, thanks to its CodeFusion Studio, which includes an IDE, a software development kit, and coding tools. Hear more about it on this week's Embedded Executives podcast, where I spoke to Rob Oshana, Analog Devices' Senior Vice President of Software and Digital Platforms.

Topics covered in this episode: The PSF has withdrawn a $1.5 million proposal to US government grant program A Binary Serializer for Pydantic Models T-strings: Python's Fifth String Formatting Technique? Cronboard Extras Joke Watch on YouTube About the show Sponsored by us! Support our work through: Our courses at Talk Python Training The Complete pytest Course Patreon Supporters Connect with the hosts Michael: @mkennedy@fosstodon.org / @mkennedy.codes (bsky) Brian: @brianokken@fosstodon.org / @brianokken.bsky.social Show: @pythonbytes@fosstodon.org / @pythonbytes.fm (bsky) Join us on YouTube at pythonbytes.fm/live to be part of the audience. Usually Monday at 10am PT. Older video versions available there too. Finally, if you want an artisanal, hand-crafted digest of every week of the show notes in email form? Add your name and email to our friends of the show list, we'll never share it. Brian #1: The PSF has withdrawn a $1.5 million proposal to US government grant program Related post from Simon Willison ARS Technica: Python plan to boost software security foiled by Trump admin's anti-DEI rules The Register: Python Foundation goes ride or DEI, rejects government grant with strings attached In Jan 2025, the PSF submitted a proposal for a US NSF grant under the Safety, Security, and Privacy of Open Source Ecosystems program. After months of work by the PSF, the proposal was recommended for funding. If the PSF accepted it, however, they would need to agree to the some terms and conditions, including, affirming that the PSF doesn't support diversity. The restriction wouldn't just be around the security work, but around all activity of the PSF as a whole. And further, that any deemed violation would give the NSF the right to ask for the money back. That just won't work, as the PSF would have already spent the money. The PSF mission statement includes "The mission of the Python Software Foundation is to promote, protect, and advance the Python programming language, and to support and facilitate the growth of a diverse and international community of Python programmers." The money would have obviously been very valuable, but the restrictions are just too unacceptable. The PSF withdrew the proposal. This couldn't have been an easy decision, that was a lot of money, but I think the PSF did the right thing. Michael #2: A Binary Serializer for Pydantic Models 7× Smaller Than JSON A compact binary serializer for Pydantic models that dramatically reduces RAM usage compared to JSON. The library is designed for high-load systems (e.g., Redis caching), where millions of models are stored in memory and every byte matters. It serializes Pydantic models into a minimal binary format and deserializes them back with zero extra metadata overhead. Target Audience: This project is intended for developers working with: high-load APIs in-memory caches (Redis, Memcached) message queues cost-sensitive environments where object size matters Brian #3: T-strings: Python's Fifth String Formatting Technique? Trey Hunner Python 3.14 has t-strings. How do they fit in with the rest of the string story? History percent-style (%) strings - been around for a very long time string.Template - and t.substitute() - from Python 2.4, but I don't think I've ever used them bracket variables and .format() - Since Python 2.6 f-strings - Python 3.6 - Now I feel old. These still seem new to me t-strings - Python 3.14, but a totally different beast. These don't return strings. Trey then covers a problem with f-strings in that the substitution happens at definition time. t-strings have substitution happen later. this is essentially “lazy string interpolation” This still takes a bit to get your head around, but I appreciate Trey taking a whack at the explanation. Michael #4: Cronboard Cronboard is a terminal application that allows you to manage and schedule cronjobs on local and remote servers. With Cronboard, you can easily add, edit, and delete cronjobs, as well as view their status. ✨ Features ✔️ Check cron jobs ✔️ Create cron jobs with validation and human-readable feedback ✔️ Pause and resume cron jobs ✔️ Edit existing cron jobs ✔️ Delete cron jobs ✔️ View formatted last and next run times ✔️ Accepts special expressions like @daily, @yearly, @monthly, etc. ✔️ Connect to servers using SSH, using password or SSH keys ✔️ Choose another user to manage cron jobs if you have the permissions to do so (sudo) Extras Brian: PEP 810: Explicit lazy imports, has been unanimously accepted by steering council Lean TDD book will be written in the open. TOC, some details, and a 10 page introduction are now available. Hoping for the first pass to be complete by the end of the year. I'd love feedback to help make it a great book, and keep it small-ish, on a very limited budget. Joke: You are so wrong!

Honeycomb's VP of Marketing Shabih Syed reveals why traditional observability is dead and how AI-powered tools are transforming the way engineers debug production systems, with real examples.Topics Include:Observability is how you understand and troubleshoot your production systems in real-timeShabih's 18-year journey: developer to product manager to marketing VP shares unique perspectiveAI coding assistants are fundamentally changing how fast engineers ship code to productionCustomer patience is gone - one checkout failure means losing them foreverOver 90% of engineers now "vibe code" with AI, creating new complexityObservability costs are spiraling - engineers forced to limit logging, creating debugging dead-endsHoneycomb reimagines observability: meeting expectations, reducing complexity, breaking the cost curveMajor customers like Booking.com and Intercom already transforming with AI-native observabilityMCP server brings production data directly into your IDE for real-time AI assistanceCanvas enables plain English investigations to find "unknown unknowns" before they become problemsAnomaly detection helps junior engineers spot issues they wouldn't know to look forStatic dashboards are dead - AI-powered workflows are the future of system observationParticipants:Shabih Syed - VP Product Marketing, Honeycomb.io See how Amazon Web Services gives you the freedom to migrate, innovate, and scale your software company at https://aws.amazon.com/isv/

Pre konsolidáciu zníži rezort kultúry počty pracovných miest, môže sa to týkať približne štyroch stoviek ľudí, uviedol generálny tajomník služobného úradu ministerstva kultúry Lukáš Machala v relácii Ide o pravdu.

Today, we're talking about building real AI products with foundation models. Not toy demos, not vibes. We'll get into the boring dashboards that save launches, evals that change your mind, and the shift from analyst to AI app builder. Our guide is Hugo Bowne-Anderson, educator, podcaster, and data scientist, who's been in the trenches from scalable Python to LLM apps. If you care about shipping LLM features without burning the house down, stick around. Episode sponsors Posit NordStellar Talk Python Courses Links from the show Hugo Bowne-Anderson: x.com Vanishing Gradients Podcast: vanishinggradients.fireside.fm Fundamentals of Dask: High Performance Data Science Course: training.talkpython.fm Building LLM Applications for Data Scientists and Software Engineers: maven.com marimo: a next-generation Python notebook: marimo.io DevDocs (Offline aggregated docs): devdocs.io Elgato Stream Deck: elgato.com Sentry's Seer: talkpython.fm The End of Programming as We Know It: oreilly.com LorikeetCX AI Concierge: lorikeetcx.ai Text to SQL & AI Query Generator: text2sql.ai Inverse relationship enthusiasm for AI and traditional projects: oreilly.com Watch this episode on YouTube: youtube.com Episode #526 deep-dive: talkpython.fm/526 Episode transcripts: talkpython.fm Theme Song: Developer Rap

Stojí za úspechom najväčších hereckých hviezd, no jej práca sa odohráva mimo svetiel reflektorov. Petra Svarinská je herecká agentka, manažérka a strategička, ktorá pomáha formovať kariéry slávnych mien. V zozname klientov nechýba Táňa Pauhofová, Judit Pecháček, Milan Ondrík či Antónia Lišková. Celkom prvou klientkou však bola jej mladšia sestra - hrdinka seriálu Dunaj, k vašim službám Kristína Svarinská. „Ja som to nejak neplánovala. Ono sa to vyvinulo čiste organicky,“ vrátila sa v relácii Ide o nás ku svojim začiatkom Petra. Pôvodne sa orientovala viac na prácu kastingovej režisérky, no po skúsenosti s Kristínou sa začali jazýčky váh preklápať viac smerom k zastupovaniu hercov.  Jej práca však nie je len o dohadovaní zmlúv a honorárov. Je to komplexný proces, v ktorom sa stáva partnerkou herca. Spoločne budujú značku a rozhodujú o tom, akým smerom sa bude kariéra uberať. „Sme vlastne partneri. Som taký sprievodca pri jeho kariére,“ vysvetľuje Svarinská, ktorá rieši všetko od zmluvných podmienok, cez castingy až po dlhodobú stratégiu. Niekedy to znamená aj presvedčiť herca, aby prijal menšiu úlohu vo výnimočnom projekte.  Kľúčom k jej prístupu je jednoduché, no zásadné pravidlo: „Človek musí mať hercov rád.“ Práve tento vzťah jej umožňuje nielen profesionálne, ale aj ľudsky viesť svojich klientov cez nástrahy filmového a televízneho sveta. V posledných rokoch sa výrazne mení – najmä s nástupom dlhodobých seriálov, ktoré si vyžadujú úplne inú stratégiu. Svarinská niekoľko rokov aktívne pracuje aj na tom, aby sa jej herci presadili aj v zahraničí. Spolupracuje s agentmi v Londýne či Amerike a verí, že slovenskí a českí herci majú šancu preraziť. Jednou z najdôležitejších podmienok je podľa nej špičková jazyková vybavenosť. Kto ju má? Aj to sa dozviete v našom rozhovore, ktorý je plný zaujímavých odhalení zo zákulisia filmového priemyslu. Ako vyzerá bežný pracovný deň hereckej agentky? Čo si myslí o umelej inteligencii, ktorá by mohla nahradiť živých hercov? A akú radu by dala svojmu 20-ročnému ja, ktoré stálo na začiatku kariéry? To všetko a ešte omnoho viac sa dozviete v novej epizóde Ide o nás (Rozhovory so Zdenom Gáfrikom).

Hypotéza 38: Ako Božia milosť často učí tých, ktorí sa o seba starajú a zverujú sa do jeho prozreteľnosti, ktorá ich vedie prostredníctvom jednoduchých ľudí a cudzincov; pokorní sa neodmietajú učiť od každého, koho môžu stretnúť.   Filokalia Live - pravidelné online formačné stretnutia. Zámerom je spoznávanie a osvojovanie umenia duchovného života štúdiom učenia svätých otcov. Štvrtkové stretnutia sú venované uvažovaniu nad dielom Evergetinos. Ide o rozsiahlu zbierku výrokov a krátkych príbehov zo života púštnych otcov, ktorá bola zostavená mníchom Pavlom v 11. storočí. Každá kapitola dáva dôkladné vysvetlenie predstavenej témy a postupne čitateľa sprevádza od položenia základných kameňov duchovného život až po jeho výšiny. Stretnutia sa konajú každý pondelok a štvrtok o 20.00 hod. V prípade záujmu sa môžete zaregistrovať a e-mailom Vám bude zaslaný link pre vstup na stretnutie.  

Ryan Carson (ex-Treehouse, Intel; now Builder-in-Residence at Sourcegraph's AMP) shares his origin story and a practical playbook for shipping software with AI agents. We cover why “tokens aren't cheap,” how AMP made pro-level coding free via developer ads, a concrete workflow (PRD → atomic dev tasks → agent execution with self-tests), and why managers should spend time as ICs “managing AI.” We close with advice for raising AI-native kids and a perspective on this moment in tech (think integrated circuit–level shift).Timestamps00:00 – The beginning of intelligence: how LLMs changed Ryan's view of computing00:23 – Apple IIe → Turbo Pascal → Computer Science: the maker bug bites03:20 – DropSend: early SaaS, Dropbox name clash, first acquisition04:30 – Treehouse: teaching coding without a CS degree; $20M raised, acquired in 202105:02 – The “bigger than a computer” moment: discovering LLMs06:15 – Joining Intel: learning GPUs and the scale of silicon (“my adult internship”)07:09 – Building an AI divorce assistant → joining AMP as Builder-in-Residence09:38 – AMP vs ChatGPT/Claude/Cursor: agentic coding with contextual developer ads11:09 – Token economics: why AI isn't really cheap17:27 – Frontier vs Flash models (Sonnet 4.5 vs Gemini 2.5) — how costs scale21:31 – Private startup: vertical AI for specialized domains22:36 – The new wave of small, vertical AI businesses23:01 – Live demo: building a news app end-to-end with AMP28:18 – How to plan like a pro: write the PRD before you build30:02 – “Outsource the work, not your thinking.”32:28 – Turning PRDs into atomic tasks (1.0, 1.1…)35:50 – Competing in an AI world = planning well36:28 – Managers should schedule IC time to “manage AI”37:14 – Designing feedback loops so agents can test themselves39:47 – “AI lied to me”: why verifiable tests matter41:11 – Raising AI-native kids: build trust, context, and agency43:59 – “We're living in the integrated circuit moment of intelligence.”Tools & Technologies MentionedAMP (Sourcegraph) – Agentic coding tool/IDE copilot that plans, edits, and ships code. Now offers a high-end, ad-supported free tier; ads are contextual for developers and don't influence code outputs.Sourcegraph (Code Search) – Parent company; enterprise code intelligence/search.ChatGPT / Claude – General-purpose LLM assistants commonly used alongside coding agents.Cursor / Windsurf – AI-first code editors that integrate LLMs for completion and refactors.Bolt / Lovable – Text-to-app builders for rapid prototyping from prompts.WhisperFlow / SuperWhisper – Voice-to-text tools for fast prompting and dictation.Anthropic Sonnet 4.5 – Frontier-grade reasoning/coding model; powerful but pricier per token.Google Gemini 2.5 Flash – Fast, lower-cost model; “good enough” for many workloads.Auth0 (example) – Authentication-as-a-service mentioned as a contextual ad use case.GPUs / TPUs – Compute for training/inference; token cost drivers behind AI pricing.PRD + Atomic Tasks Workflow – Ryan's method: record spec → generate PRD → expand to dot-notated tasks → let the agent implement.Self-testing Scripts – Ask agents to generate runnable tests/health checks and loop until passing to reduce back-and-forth and prevent “it passed” hallucinations.Family ChatGPT Accounts – Tip for raising AI-native kids; teach sourcing, context, and trust calibration.Subscribe at⁠ thisnewway.com⁠ to get the step-by-step playbooks, tools, and workflows.

Send us a textQuantum threats aren't waiting politely on the horizon, and neither should we. We kick off with Signal's bold move to deploy post-quantum encryption, unpacking the “belt and suspenders” approach that blends classical cryptography with quantum-resistant algorithms. No jargon traps—just clear takeaways on why this matters for privacy, resilience, and the pressure it puts on other messaging platforms to evolve. We point you to smart reads from Ars Technica and Bruce Schneier that make the technical guts approachable and actionable.From there, we switch gears into a focused CISSP Domain 8 walkthrough: how to weave security into every phase of the software development lifecycle. We talk practical integration across waterfall, agile, and DevOps; show why change management, continuous monitoring, and application-aware incident response are non-negotiable; and explain how maturity models like CMMI and BSIMM help teams move from reactive to repeatable. We also break down the developer's toolbox—secure language choices, vetted libraries with SCA, hardened runtimes, and IDE plugins that surface issues in real time—so teams can ship faster without trading away safety.Speed meets rigor in the CI/CD pipeline, where shift-left security comes alive with SAST, DAST, and SOAR-driven checks. We cover repository hygiene, secret scanning, and how to measure effectiveness with audit trails and risk analysis that map code issues to business impact. You'll get a clear view of third-party risk across COTS and open source, the shared responsibility model for SaaS, PaaS, and IaaS, and the daily practices that keep APIs from leaking data: least privilege, strict authorization, input validation, and rate limiting. We close with software-defined security—policies as code—bringing consistency, versioning, and automation to your defenses. Subscribe, share with a teammate who owns your pipeline, and leave a review to tell us the next Domain 8 topic you want us to deep-dive.Gain exclusive access to 360 FREE CISSP Practice Questions at FreeCISSPQuestions.com and have them delivered directly to your inbox! Don't miss this valuable opportunity to strengthen your CISSP exam preparation and boost your chances of certification success. Join now and start your journey toward CISSP mastery today!

Santo Espírito (parte 10) - Gabriel Manzoni by IDE

Ide O'Carroll is a Social Researcher, author, and former teacher who undertook a 30-year project for her latest book.In this unique book, we hear from Irish women who stayed living on the island, who did not emigrate, describe their lives and perspectives on a dramatically changed social context from the 1990s to 2023.‘Thirty Years of Change Through Women's Eyes' releases officially tomorrow, and Ide joins Seán to discuss.

Building a UI in Python usually means choosing between "quick and limited" or "powerful and painful." What if you could write modern, component-based web apps in pure Python and still keep full control? NiceGUI, pronounced "Nice Guy" sits on FastAPI with a Vue/Quasar front end, gives you real components, live updates over websockets, and it's running in production at Zauberzeug, a German robotic company. On this episode, I'm talking with NiceGUI's creators, Rodja Trappe and Falko Schindler, about how it works, where it shines, and what's coming next. With version 3.0 releasing around the same time this episode comes out, we spend the end of the episode celebrating the 3.0 release. Episode sponsors Posit Agntcy Talk Python Courses Links from the show Rodja Trappe: github.com Falko Schindler: github.com NiceGUI 3.0.0 release: github.com Full LLM/Agentic AI docs instructions for NiceGUI: github.com Zauberzeug: zauberzeug.com NiceGUI: nicegui.io NiceGUI GitHub Repository: github.com NiceGUI Authentication Examples: github.com NiceGUI v3.0.0rc1 Release: github.com Valkey: valkey.io Caddy Web Server: caddyserver.com JustPy: justpy.io Tailwind CSS: tailwindcss.com Quasar ECharts v5 Demo: quasar-echarts-v5.netlify.app AG Grid: ag-grid.com Quasar Framework: quasar.dev NiceGUI Interactive Image Documentation: nicegui.io NiceGUI 3D Scene Documentation: nicegui.io Watch this episode on YouTube: youtube.com Episode #525 deep-dive: talkpython.fm/525 Episode transcripts: talkpython.fm Theme Song: Developer Rap

Topics covered in this episode: Cyclopts: A CLI library * The future of Python web services looks GIL-free* * Free-threaded GC* * Polite lazy imports for Python package maintainers* Extras Joke Watch on YouTube About the show Sponsored by us! Support our work through: Our courses at Talk Python Training The Complete pytest Course Patreon Supporters Connect with the hosts Michael: @mkennedy@fosstodon.org / @mkennedy.codes (bsky) Brian: @brianokken@fosstodon.org / @brianokken.bsky.social Show: @pythonbytes@fosstodon.org / @pythonbytes.fm (bsky) Join us on YouTube at pythonbytes.fm/live to be part of the audience. Usually Monday at 10am PT. Older video versions available there too. Finally, if you want an artisanal, hand-crafted digest of every week of the show notes in email form? Add your name and email to our friends of the show list, we'll never share it. Michael #1: Cyclopts: A CLI library A CLI library that fixes 13 annoying issues in Typer Much of Cyclopts was inspired by the excellent Typer library. Despite its popularity, Typer has some traits that I (and others) find less than ideal. Part of this stems from Typer's age, with its first release in late 2019, soon after Python 3.8's release. Because of this, most of its API was initially designed around assigning proxy default values to function parameters. This made the decorated command functions difficult to use outside of Typer. With the introduction of Annotated in python3.9, type-hints were able to be directly annotated, allowing for the removal of these proxy defaults. The 13: Argument vs Option Positional or Keyword Arguments Choices Default Command Docstring Parsing Decorator Parentheses Optional Lists Keyword Multiple Values Flag Negation Help Defaults Validation Union/Optional Support Adding a Version Flag Documentation Brian #2: The future of Python web services looks GIL-free Giovanni Barillari “Python 3.14 was released at the beginning of the month. This release was particularly interesting to me because of the improvements on the "free-threaded" variant of the interpreter. Specifically, the two major changes when compared to the free-threaded variant of Python 3.13 are: Free-threaded support now reached phase II, meaning it's no longer considered experimental The implementation is now completed, meaning that the workarounds introduced in Python 3.13 to make code sound without the GIL are now gone, and the free-threaded implementation now uses the adaptive interpreter as the GIL enabled variant. These facts, plus additional optimizations make the performance penalty now way better, moving from a 35% penalty to a 5-10% difference.” Lots of benchmark data, both ASGI and WSGI Lots of great thoughts in the “Final Thoughts” section, including “On asynchronous protocols like ASGI, despite the fact the concurrency model doesn't change that much – we shift from one event loop per process, to one event loop per thread – just the fact we no longer need to scale memory allocations just to use more CPU is a massive improvement. ” “… for everybody out there coding a web application in Python: simplifying the concurrency paradigms and the deployment process of such applications is a good thing.” “… to me the future of Python web services looks GIL-free.” Michael #3: Free-threaded GC The free-threaded build of Python uses a different garbage collector implementation than the default GIL-enabled build. The Default GC: In the standard CPython build, every object that supports garbage collection (like lists or dictionaries) is part of a per-interpreter, doubly-linked list. The list pointers are contained in a PyGC_Head structure. The Free-Threaded GC: Takes a different approach. It scraps the PyGC_Head structure and the linked list entirely. Instead, it allocates these objects from a special memory heap managed by the "mimalloc" library. This allows the GC to find and iterate over all collectible objects using mimalloc's data structures, without needing to link them together manually. The free-threaded GC does NOT support "generations” By marking all objects reachable from these known roots, we can identify a large set of objects that are definitely alive and exclude them from the more expensive cycle-finding part of the GC process. Overall speedup of the free-threaded GC collection is between 2 and 12 times faster than the 3.13 version. Brian #4: Polite lazy imports for Python package maintainers Will McGugan commented on a LI post by Bob Belderbos regarding lazy importing “I'm excited about this PEP. I wrote a lazy loading mechanism for Textual's widgets. Without it, the entire widget library would be imported even if you needed just one widget. Having this as a core language feature would make me very happy.” https://github.com/Textualize/textual/blob/main/src/textual/widgets/__init__.py Well, I was excited about Will's example for how to, essentially, allow users of your package to import only the part they need, when they need it. So I wrote up my thoughts and an explainer for how this works. Special thanks to Trey Hunner's Every dunder method in Python, which I referenced to understand the difference between __getattr__() and __getattribute__(). Extras Brian: Started writing a book on Test Driven Development. Should have an announcement in a week or so. I want to give folks access while I'm writing it, so I'll be opening it up for early access as soon as I have 2-3 chapters ready to review. Sign up for the pythontest newsletter if you'd like to be informed right away when it's ready. Or stay tuned here. Michael: New course!!! Agentic AI Programming for Python I'll be on Vanishing Gradients as a guest talking book + ai for data scientists OpenAI launches ChatGPT Atlas https://github.com/jamesabel/ismain by James Abel Pets in PyCharm Joke: You're absolutely right

In this episode, host Etienne Nichols and guest Dr. Allison Komiyama, CEO and Founder of Blue Stocking Health, dive into a fascinating dialogue about the language used in healthcare and MedTech, particularly the terms patient, customer, and user. They explore how these words influence the perception of care, service, and the entire medical device development process. The conversation touches on the friction and inefficiencies that arise when the relationship dynamic is unclear, highlighting the different nuances between passively receiving treatment and being an active consumer of health services.The discussion delves into the historical context of the word "patient," which is rooted in the Latin patior, meaning 'to suffer.' Dr. Komiyama shares insights from industry conferences, noting that many individuals prefer to be called a "person" or an "empowered patient" rather than a passive sufferer. This ties directly into the growing movement of individuals seeking to own their health and be active participants in their care, fueled by readily available information and a focus on health span over just disease treatment.Ultimately, the key takeaway for MedTech innovators is the importance of understanding their end-user and tailoring their language—in labeling, clinical studies, and human factors testing—to align with the user's preferred terminology. The shift from "caregiver" to "care partner" is highlighted as a prime example of evolving language that acknowledges a collaborative, mutual relationship, moving away from a hierarchical structure to one of shared purpose.Key Timestamps[0:01:25] - Introduction to Dr. Allison Komiyama and Blue Stocking Health's mission to amplify the good of MedTech.[0:04:14] - Discussion begins: Patient vs. Customer vs. User in MedTech.[0:06:05] - The etymology of "patient" (patior, to suffer) and the push for "person" or "empowered patient."[0:08:22] - Historical context: Passivity of the patient role and the doctor's assumed knowledge.[0:09:50] - The impact of consumerism, AI, and the "health span" movement on patient empowerment.[0:12:35] - The value of seeking multiple opinions and the role of patient priorities in customizing care.[0:15:30] - Shifting terminology: Why "caregiver" is moving toward "care partner."[0:18:22] - How language diversity enriches the conversation and enhances communication.[0:21:00] - Tying diverse language use to MedTech innovation and product development.[0:22:15] - The importance of understanding end-user biases and assumptions in MedTech.[0:24:25] - Impactful personal stories: How specific interactions define a positive care experience.[0:29:10] - Concluding thoughts: Why plurality and qualifiers (e.g., "empowered patient") may be the ideal goal.Quotes"I think there's a lot of folks at FDA even that we're like, we don't want to use the word patient. We want to use the word person. And patient actually comes from the term patior, which means to suffer." - Dr. Allison KomiyamaTakeawaysRegulatory & Clinical Strategy: When defining the target population for your device—in 510k, IDE, or PMA submissions—be mindful of the terminology. Consider using terms like "end-user," "person living with [condition]," or "care partner" alongside "patient" to reflect a modern, inclusive understanding of...

Jeho pseudonym Neuer je dnes názvom úspešného kriminálneho seriálu, ktorý vznikol na motívy jeho bestsellerov. Nie každý vie, že autor Václav Neuer, vlastným menom Kincl, nie je len spisovateľom s bujnou fantáziou. Príbehy, ktoré dnes s napätím čítajú tisíce ľudí, kedysi sám vyšetroval ako elitný kriminalista na oddelení vrážd. Autentické skúsenosti z divokých 90. rokov sú základom úspechu jeho kníh. O drsnej realite boja s mafiou, ktorá bola vtedy na vrchole moci, prehovoril otvorene v relácii Ide o nás. Psychický nápor a hrôzy, ktoré videl na miestach činu, sa naučil zvládať absolútnym sústredením na prácu. Dnes tieto zážitky premieňa na napínavé príbehy, v ktorých však, na rozdiel od reality, vždy zvíťazí spravodlivosť. „Moje knihy sú tak trochu rozprávky pre dospelých. V nich je zlo vždy potrestané. V skutočnosti to tak, žiaľ, nebolo,“ dodáva s tým, že jeho cieľom je predovšetkým baviť čitateľa. Cesta od policajta k spisovateľovi bola pre neho prirodzeným naplnením snov. „Mal som obrovské šťastie, že som celý život robil to, čo ma baví, a že sa mi sny plnili tak nejako postupne a nenásilne. Som za to nesmierne vďačný,“ pokračoval autor, ktorého predlohu vzali aj tvorcovia jojkárskeho seriálu Neuer. Prvé oslovanie prišlo už pred troma rokmi a reakcia Václava Neuera bola prekvapivá. Myslel si, že si z neho robia žarty. Nerobili. Na obrazovkách je aktuálne miniséria, v ktorej hrá hlavnú rolu Marián Miezga a sekundujú mu herci ako Marko Igonda, Jana Kvantíková či Ladislav Bédi. Aj o nakrúcaní či rozhovoroch s hercami prehovoril Václav Neuer v našom štúdiu. Dozviete sa tiež, či si spomína ešte na prvú vraždu, ktorú vyšetroval, či má vo vlastnom zozname nevyriešený prípad alebo ako bojoval s pohľadom na krutosť a čo bolo pre neho najdôležitejšie pri práci vyšetrovateľa. Viac si pozrite v relácii Ide o nás.

Školská reforma nie je o likvidácii škôl, ale o spravodlivosti a rovnakom prístupe, uviedol minister školstva Tomáš Drucker (Hlas) v relácii Ide o pravdu.

Už o pár dní sa predstaví slovenským divákom ako slovenský športovec 20. storočia - krasokorčuliar Ondrej Nepela. Český herec Josef Trojan niekdajšieho olympionika zo ZOH v Sapore pred nakrúcaním nepoznal. "Je to vlastne smutné a poukazuje, že jeho odkaz bol vo vtedajšom komunistickom Československu, po jeho odchode do západného Nemecka, takmer úplne potlačený a odsunutý na vedľajšiu koľaj. Veľmi málo sa o ňom potom písalo. Jeho hviezda teda nepokračovala v žiarení, skôr zhasínala. Aj to je dôležitý dôvod, prečo točiť filmy o podobných osudoch a pripomínať si ich," uviedol v relácii Ide o nás potomok zo slávnej hereckej rodiny. Pre úlohu Nepelu sa Josef Trojan snažil vycibriť si slovenčinu a, samozrejme, nechýbali ani tréningy na ľade. Najradšej vraj rozpráva príhodu, že keď sa na ľade ocitol so svojím dablérom - slovenským krasokorčuliarom Adamom Hagarom - štáb si pri nakrúcaní scén mýlil. "Bolo fajn zistenie, že som sa v základných prvkoch dokázal pohybovať s takou samozrejmosťou, až to mohlo niekoho pomýliť," vysvetlil spokojne Trojan. Slovo spokojnosť však v jeho profesionálnom slovníku nie je časté. A dokonalosť tiež nie - vraj sa o ňu ani nesnaží, chce sa však príbližiť tomu, aby stvárnil každú postavu čo najlepšie. V relácii sme sa pozreli na obety, ktoré si pýtala rola Nepelu, ale aj motivácie a zručnosti, ktoré si Josef Trojan zobral z predchádzajúcich projektov.  Nehovorili sme však len o príprave na nakrúcanie. Témou sa stali aj jeho názory na politiku a občianske postoje. Hovorili sme o rodine, keďže jeho otcom je herec Ivan Trojan a mamou herečka Klára Pollertová. A nevyhli sme sa ani téme duševných problémov, ktoré musel v minulosti riešiť. Hovoriť o nich sa nehanbí a pre ľudí, ktorí zľahčujú mentálne problémy, má jasný odkaz. Aký? Pozrite si v novej epizóde Ide o nás.

Rozvody budú jednoduchšie a súdy sa prestanú pýtať na váš intímny život. Zaniká bezdpodielové spoluvlastníctvo manželov (BSM) a zavádzajú sa (pred)manželské zmluvy. Ak si niekto zmení pohlavie, štát ho automaticky rozvedie.Pri dedičstve príde celá séria radikálnych zmien - rodičia budú môcť rozdeliť dedičstvo medzi svoje deti takmer ľubovoľne, uzatvárať s nimi zmluvy o doopatrovaní, a kto napadne závet na súde, vysúdi menej ako doteraz.Socialistický zákon z roku 1964 úplne zmizne a od roku 2027 ho v prípade schválenia nahradí nový zákonník, ktorý pohltí aj zákon o rodine alebo celý obchodný zákonník. Ide tak o najväčšiu zmenu zákona s najväčším praktickým dosahom na denný život obyčajných ľudí od vzniku modernej Slovenskej republiky.Budete počuť ministra spravodlivosti Borisa Suska (SMER), šéfa rekodifikačnej komisie Mareka Števčeka, opozičnú poslankyňu Irenu Bihariovú z PS a advokáta Milana Ficeka.Nahrával Peter Hanák.

Imagine a world where handoff no longer exists and designers are moving fluidly in code…[Drew Wilson](https://x.com/drewwilson) is one of the people pulling that future into the present so this week's episode is a deep dive into his vision for the new design tool [Opacity](https://opacity.app/).Some highlights:- How team structures are changing- How to stand out when everyone is a builder- What design's “Github moment” will look like- The fracturing of the market for design talent- How Drew is approaching this startup differently- Where the new technical threshold is for designers- + a lot moreDrew is also building his new IDE called Loop - https://loupe.build/

Python in 2025 is different. Threads really are about to run in parallel, installs finish before your coffee cools, and containers are the default. In this episode, we count down 38 things to learn this year: free-threaded CPython, uv for packaging, Docker and Compose, Kubernetes with Tilt, DuckDB and Arrow, PyScript at the edge, plus MCP for sane AI workflows. Expect practical wins and migration paths. No buzzword bingo, just what pays off in real apps. Join me along with Peter Wang and Calvin Hendrix-Parker for a fun, fast-moving conversation. Episode sponsors Seer: AI Debugging, Code TALKPYTHON Agntcy Talk Python Courses Links from the show Calvin Hendryx-Parker: github.com/calvinhp Peter on BSky: @wang.social Free-Threaded Wheels: hugovk.github.io Tilt: tilt.dev The Five Demons of Python Packaging That Fuel Our ...: youtube.com Talos Linux: talos.dev Docker: Accelerated Container Application Development: docker.com Scaf - Six Feet Up: sixfeetup.com BeeWare: beeware.org PyScript: pyscript.net Cursor: The best way to code with AI: cursor.com Cline - AI Coding, Open Source and Uncompromised: cline.bot Watch this episode on YouTube: youtube.com Episode #524 deep-dive: talkpython.fm/524 Episode transcripts: talkpython.fm Theme Song: Developer Rap

Topics covered in this episode: * djrest2 -* A small and simple REST library for Django based on class-based views. Github CLI caniscrape - Know before you scrape. Analyze any website's anti-bot protections in seconds. *

Topics covered in this episode: * PyPI+* * uv-ship - a CLI-tool for shipping with uv* * How fast is 3.14?* * air - a new web framework built with FastAPI, Starlette, and Pydantic.* Extras Joke Watch on YouTube About the show Sponsored by us! Support our work through: Our courses at Talk Python Training The Complete pytest Course Patreon Supporters Connect with the hosts Michael: @mkennedy@fosstodon.org / @mkennedy.codes (bsky) Brian: @brianokken@fosstodon.org / @brianokken.bsky.social Show: @pythonbytes@fosstodon.org / @pythonbytes.fm (bsky) Join us on YouTube at pythonbytes.fm/live to be part of the audience. Usually Monday at 10am PT. Older video versions available there too. Finally, if you want an artisanal, hand-crafted digest of every week of the show notes in email form? Add your name and email to our friends of the show list, we'll never share it. Michael #1: PyPI+ Very nice search and exploration tool for PyPI Minor but annoying bug: content-types ≠ content_types on PyPI+ but they are in Python itself. Minimum Python version seems to be interpreted as max Python version. See dependency graphs and more Examples content-types jinja-partials fastapi-chameleon Brian #2: uv-ship - a CLI-tool for shipping with uv “uv-ship is a lightweight companion to uv that removes the risky parts of cutting a release. It verifies the repo state, bumps your project metadata and optionally refreshes the changelog. It then commits, tags & pushes the result, while giving you the chance to review every step.” Michael #3: How fast is 3.14? by Miguel Grinberg A big focus on threaded vs. non-threaded Python Some times its faster, other times, it's slower Brian #4: air - a new web framework built with FastAPI, Starlette, and Pydantic. An very new project in Alpha stage by Daniel & Audrey Felderoy, the “Two Scoops of Django” people. Air Tags are an interesting thing. Also Why? is amazing “Don't use AIR” “Every release could break your code! If you have to ask why you should use it, it's probably not for you.” “If you want to use Air, you can. But we don't recommend it.” “It'll likely infect you, your family, and your codebase with an evil web framework mind virus, , …” Extras Brian: Python 3.15a1 is available uv python install 3.15 already works Python lazy imports you can use today - one of two blog posts I threatened to write recently Testing against Python 3.14 - the other one Free Threading has some trove classifiers Michael: Blog post about the book: Talk Python in Production book is out! In particular, the extras are interesting. AI Usage TUI Show me your ls Helium Browser is interesting. But also has Python as a big role. GitHub says Languages Python 97.4%

Python typing got fast enough to feel invisible. Pyrefly is a new, open source type checker and IDE language server from Meta, written in Rust, with a focus on instant feedback and real-world DX. Today, we will dig into what it is, why it exists, and how it plays with the rest of the typing ecosystem. We have Abby Mitchell, Danny Yang, and Kyle Into from Pyrefly here to dive into the project. Episode sponsors Sentry Error Monitoring, Code TALKPYTHON Agntcy Talk Python Courses Links from the show Abby Mitchell: linkedin.com Danny Yang: linkedin.com Kyle Into: linkedin.com Pyrefly: pyrefly.org Pyrefly Documentation: pyrefly.org Pyrefly Installation Guide: pyrefly.org Pyrefly IDE Guide: pyrefly.org Pyrefly GitHub Repository: github.com Pyrefly VS Code Extension: marketplace.visualstudio.com Introducing Pyrefly: A New Type Checker and IDE Experience for Python: engineering.fb.com Pyrefly on PyPI: pypi.org InfoQ Coverage: Meta Pyrefly Python Typechecker: infoq.com Pyrefly Discord Invite: discord.gg Python Typing Conformance (GitHub): github.com Typing Conformance Leaderboard (HTML Preview): htmlpreview.github.io Watch this episode on YouTube: youtube.com Episode #523 deep-dive: talkpython.fm/523 Episode transcripts: talkpython.fm Theme Song: Developer Rap

Will this be the AI update that finally brings AI agents to millions?